Výsledky vyhledávání

Akademický článek

GLOBAL MAPPING PROJECT – APPLICATIONS AND DEVELOPMENT OF VERSION 2 DATASET

Autor: T. Ubukawa, T. Nakamura, T. Otsuka, T. Iimura, N. Kishimoto, K. Nakaminami, Y. Motojima, M. Suga, Y. Yatabe, M. Koarai, T. Okatani

Publikováno v: The International Archives of the Photogrammetry, Remote Sensing and Spatial Information Sciences, Vol XXXIX-B4, Pp 51-56 (2012)

The Global Mapping Project aims to develop basic geospatial information of the whole land area of the globe, named Global Map, through the cooperation of National Mapping Organizations (NMOs) around the world. The Global Map data can be a base of glo

Externí odkaz: https://doaj.org/article/b58a12cfe61741a0a0081ad63521b51b

Zobrazit plný text záznamu

Abstract OT2-16-05: Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Positive Metastatic Breast Cancer (MBC)

Autor: Charles E. Geyer, Jr, Gong Tang, Priya Rastogi, Vicente Valero, Stephen K. Chia, Erin F. Cobain, Elias Obeid, David B. Page, Andrew S. Poklepovic, William J. Irvin, Jr., Adam M. Brufsky, Irene L. Wapnir, Jennifer M. Suga, Eleftherios (Terry) Mamounas, Norman Wolmark

Publikováno v: Cancer Research. 83:OT2-16

Background: The CLEOPATRA trial established trastuzumab, pertuzumab and a taxane (THP) as a standard of care for first line metastatic, HER2-positve breast cancer with median progression-free survival (PFS) of 18.7 months and median OS of 57 months.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44c30999f9f5e15eb575e322ba770a07
https://doi.org/10.1158/1538-7445.sabcs22-ot2-16-05

Zobrazit plný text záznamu

Phase II Study of Copanlisib in Patients With Tumors With

Autor: Senthil, Damodaran, Fengmin, Zhao, Dustin A, Deming, Edith P, Mitchell, John J, Wright, Robert J, Gray, Victoria, Wang, Lisa M, McShane, Larry V, Rubinstein, David R, Patton, P Mickey, Williams, Stanley R, Hamilton, Jennifer M, Suga, Barbara A, Conley, Carlos L, Arteaga, Lyndsay N, Harris, Peter J, O'Dwyer, Alice P, Chen, Keith T, Flaherty

Publikováno v: J Clin Oncol

Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies on the basis of matching genomic alterations. Arm Z1F evaluated copanlisib,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cfbcd9071baf869343e1deaeda8697f7
https://pubmed.ncbi.nlm.nih.gov/35133871

Zobrazit plný text záznamu

Appendix from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Autor: Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, Jennifer M. Suga, Marcus S. Noel, Jordan Berlin, Michael J. Pishvaian, Florencia Jalikis, Elizabeth M. Swisher, Philip A. Philip, Katherine A. Guthrie, E. Gabriela Chiorean

Protocol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50a4d2e0c0f632703c894986b60a2ec8
https://doi.org/10.1158/1078-0432.22483598.v1

Zobrazit plný text záznamu

Table S1 and Table S2 from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Table S1: BROCA-HR gene list Table S2: Best Response, TTP, OS in Patients with HR-DDR Defects

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aa7244ad887ba1c96708f23ce42ce3e
https://doi.org/10.1158/1078-0432.22483595

Zobrazit plný text záznamu

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Purpose:PARP inhibitors synergize with topoisomerase inhibitors, and veliparib plus modified (m) FOLFIRI (no 5-FU bolus) had preliminary activity in metastatic pancreatic cancers. This study evaluated the safety and efficacy of second-line treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29e14e2256fbd8da39e6b01f4ebec903
https://doi.org/10.1158/1078-0432.c.6531176.v1

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání